We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Reducing MRSA Test From Days to Hours

By HospiMedica staff writers
Posted on 14 Nov 2006
A rapid screening test reduces the time needed to diagnose methicillin-resistant Staphylococcus aureus (MRSA) from days to just a few hours.

There are other antibiotic-resistant bacteria, including extended-spectrum beta-lactamase (ESbL) producers and vancomycin-resistant enterococci (VRE), that have been widely detected in hospitals. More...
ESbL-producing Escherichia coli (E coli) are able to resist penicillin and antibiotics, and are found in urinary tract infections in the community as well as in hospitals. VRE are found in feces and can cause urinary-tract infections.

Acolyte Biomedica (Porton Down, UK) developed the BacLite rapid MRSA screening test, which is proving to be a powerful weapon in the battle to reduce the spread of MRSA, saving many lives each year. Several National Health Service (NHS, UK) and private U.K. hospitals are currently using the BacLite test to screen for MRSA, which is resistant to all but a few expensive and rarely-used antibiotics.

Acolyte Biomedica is now using specially equipped laboratories at Tetricus (Porton Down, UK) to develop rapid screening tests for other antibiotic-resistant bacteria. Tetricus is a bio-incubation unit, which provides a mixture of serviced office and laboratory accommodations for fast-growing biotechnology companies.

Bill Mullen, Acolyte's chief executive, said: "This not the sort of thing you can do on a conventional industrial estate without your neighbors getting worried. Tetricus provides a sophisticated and safe environment for this type of work, and businesses based here also benefit from the support and expertise at Porton Down, which is home to more than 1,000 scientists.”



Related Links:
Acolyte Biomedica
Tetricus

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Vessel Sealing Instrument
ERGOseal
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.